Increased Levels of Soluble CD206 Associated with Rapidly Progressive Interstitial Lung Disease in Patients with Dermatomyositis

Table 3

Basic clinical characteristics of DM patients with follow-up data.

	Gender (F/M)	Onset age/years	Disease course/months	Follow-up duration/months	Treatment naïve	ILD types	PGA VAS at enrollment
Patient 1	F	45	4	0.80	Yes	Without	7
Patient 2	M	46	4	30.97	Yes	Without	5
Patient 3	M	36	7	11.70	Yes	NonRP-ILD	5
Patient 4	F	37	4	7.03	No	RP-ILD	8.5
Patient 5	F	60	2	5.63	No	NonRP-ILD	2.5
Patient 6	M	27	1	5.03	No	NonRP-ILD	2
Patient 7	F	49	24	11.80	No	NonRP-ILD	4
Patient 8	F	40	2	3.47	Yes	NonRP-ILD	5
Patient 9	F	50	1	4.50	Yes	NonRP-ILD	5
Patient 10	F	59	24	5.67	No	RP-ILD	8
Patient 11	M	45	3	2.03	No	RP-ILD	6
Patient 12	F	43	36	13.33	No	NonRP-ILD	4
Patient 13	M	36	2	4.03	Yes	Without	6
Patient 14	M	39	7	6.97	No	NonRP-ILD	5
Patient 15	F	38	36	3.50	No	NonRP-ILD	7
Patient 16	M	69	9	2.83	Yes	NonRP-ILD	6
Patient 17	F	83	1	2.47	Yes	Without	4
Patient 18	F	47	5	6.17	No	NonRP-ILD	3
Patient 19	M	60	2	2.57	No	RP-ILD	3
Patient 20	F	64	29	3.50	No	NonRP-ILD	5

DM: dermatomyositis; ILD: interstitial lung disease; RP-ILD: rapidly progressive interstitial lung disease; VAS: visual analog scale; PGA: physician global assessment.